{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"}],"units":"Participants"}],"description":"Adverse events per the NCI Common Toxicity Criteria version 3.0 that were possibly, probably or definitely related to protocol treatment. See adverse event tables for specific details.","groups":[{"id":"OG000","title":"AZD2171 (Cediranib Maleate)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients who received protocol treatment were assessed for adverse events. See adverse event tables for specific details.","reportingStatus":"POSTED","timeFrame":"Daily during protocol treatment","title":"Adverse Event Rates","type":"SECONDARY","unitOfMeasure":"Participants"}